Tradestie Institutional Equity Comparison Engine

MRNA vs IBRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while IBRX counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus IBRX at 60.2x Forward P/E and -150.2% operating margin (+52.3% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against IBRX sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs IBRX 60.2x Fwd P/E
Growth & Margin Winner IBRX
Op Margin -80.8% vs -150.2% ยท YoY +29.2% vs +52.3%
Momentum & Technical Winner MRNA
1Y +706.5% vs +181.3% ยท 52W Pos 67% vs 39%
Options & Structure Winner IBRX
CONSOLIDATION (52nd %ile IV) vs BREAKDOWN (14th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
IBRX NASDAQ
ImmunityBio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.02
-8.37% 1D
Market Cap $7.0B
1M Return -27.56%
1Y Return +181.31%
Forward P/E 60.2x
Unified AI Score
61.4 / 100 BUY
Tech 75.0 Fund 69.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% IBRX +181.31% Spread: +525.14 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue IBRX Revenue MRNA Op. Margin IBRX Op. Margin Margin Edge
FY2018 $140M $0M -306.0% -209338.3% MRNA
FY2019 $60M $0M -906.8% -7095.9% MRNA
FY2020 $800M $0M -95.0% -36509.1% MRNA
FY2021 $18.5B $0M 72.0% -35361.9% MRNA
FY2022 $19.3B $0M 48.9% -146374.2% MRNA
FY2023 $6.85B $0M -61.9% -58239.5% MRNA
FY2024 $3.24B $10M -121.9% -2334.2% MRNA
FY2025 $1.94B $110M -158.1% -226.0% MRNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (6) vs IBRX (4)
Institutional Metric MRNA IBRX Criterion Row Winner
Market Capitalization Scale $80.7B $7.0B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 60.2x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x 60.2x Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +52.3% Higher Growth IBRX
Operating Margin (TTM) Profitability -80.8% -150.2% Higher Margin MRNA
Net Profit Margin Profitability -110.5% 0.0% Higher Margin IBRX
Return on Equity (ROE) Capital Efficiency -34.5% 0.0% Higher ROE IBRX
52-Week Range Position Momentum 67% ($22โ€“$281) 39% ($2โ€“$12) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 1.68ฮฒ ยท 107% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 61.4 / 100 (BUY) Higher Composite IBRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs IBRX Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IBRX BREAKDOWN
30d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live IBRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor IBRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.